ReviewThe journal of gene medicine2012
Challenges in T cell receptor gene therapy.
Review in The journal of gene medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 42 citations in OpenAlex.
- Phage display enables machine learning discovery of cancer antigen-specific TCRs.Science advances · 2025Article
- T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors.Journal of hematology & oncology · 2021Review
- Characterization of an Anti-CD5 Directed CAR T-Cell against T-Cell Malignancies.Stem cell reviews and reports · 2020Article
- Genetically Modified T-Cell Therapy for Osteosarcoma: Into the Roaring 2020s.Advances in experimental medicine and biology · 2020Review
- T Cell Reprogramming Against Cancer.Methods in molecular biology (Clifton, N.J.) · 2020Review
- T cell receptor-engineered T cells for leukemia immunotherapy.Cancer cell international · 2019Review
- Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy.Journal for immunotherapy of cancer · 2017Article
- Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice.Blood cancer journal · 2016Article
- Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Genetically modified T cells in cancer therapy: opportunities and challenges.Disease models & mechanisms · 2015Review
- Genetically modified T-cell therapy for osteosarcoma.Advances in experimental medicine and biology · 2014Review
- Genetically modified T cells to target glioblastoma.Frontiers in oncology · 2013Review
- Immunotherapy with gene-modified T cells: limiting side effects provides new challenges.Gene therapy · 2013Review
- A new cloning and expression system yields and validates TCRs from blood lymphocytes of patients with cancer within 10 days.Nature medicine · 2013Article
- Potential limitations of the NSG humanized mouse as a model system to optimize engineered human T cell therapy for cancer.Human gene therapy methods · 2013Article
- Gene-engineered T cells for cancer therapy.Nature reviews. Cancer · 2013Review
- SHP-1 phosphatase activity counteracts increased T cell receptor affinity.The Journal of clinical investigation · 2013Article
- High-quality and high-avidity T cell clones specific for tumor-associated antigens and how to find them.Oncoimmunology · 2012Article
- Development of safer gene delivery systems to minimize the risk of insertional mutagenesis-related malignancies: a critical issue for the field of gene therapy.ISRN oncology · 2012Article
- Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
The function of T lymphocytes as orchestrators and effectors of the adaptive immune response is directed by the specificity of their T cell receptors (TCRs). By transferring into T cells the genes encoding antigen-specific receptors, the functional activity of large populations of T cells can be redirected against defined targets including virally infected or cancer cells. The potential of therapeutic T cells to traffic to sites of disease, to expand and to persist after a single treatment remains a major advantage over the currently available immunotherapies that use monoclonal antibodies. Here we review recent progress in the field of TCR gene therapy, outlining challenges to its successful implementation and the strategies being used to overcome them. We detail strategies used in the optimization of affinity and surface expression of the introduced TCR, the choice of T cell subpopulations for gene transfer, and the promotion of persistence of gene-modified T cells in vivo. We review the safety concerns surrounding the use of gene-modified T cells in patients, discussing emerging solutions to these problems, and describe the increasingly positive results from the use of gene-modified T cells in recent clinical trials of adoptive cellular immunotherapy. The increasing sophistication of measures to ensure the safety of engineered T cells is accompanied by an increasing number of clinical trials: these will be essential to guide the effective translation of cellular immunotherapy from the laboratory to the bedside.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.